Sarepta Will Present Neuromuscular Research in San Antonio
The company will share seven research posters during a scientific meeting taking place from September 25-27, 2026.
Updated on Sept. 24, 2026 in Biotech
Live Poll
Do you trust that pharmaceutical companies are transparent about the safety risks of new gene therapies?
Sarepta Therapeutics is set to present findings from its neuromuscular portfolio at the 27th Annual Neuromuscular Study Group Scientific Meeting in San Antonio, Texas. The presentations include new data from the Phase 4 ENDURE study regarding Duchenne muscular dystrophy treatments.
Why it matters
The company aims to share insights into the real-world use of its therapies to support their ongoing clinical profiles. These findings provide critical data on safety and efficacy in patients receiving specific treatment regimens.
Sarepta will showcase seven posters during the 27th annual meeting, including results from the Phase 4 ENDURE study. This multi-center study focuses on safety metrics for patients treated with delandistrogene moxeparvovec.
The players
Sarepta Therapeutics
A biotechnology company headquartered in Cambridge, Massachusetts, that focuses on the discovery and development of genetic medicines for rare diseases.
The details
The presentations will focus on the real-world application of delandistrogene moxeparvovec, including patient data involving prophylactic immunosuppression with sirolimus. Researchers will share these results during a dedicated poster session on September 25, 2026.
Timeline
September 25-27, 2026: The 27th Annual Neuromuscular Study Group Scientific Meeting occurs.
September 25, 2026: Poster session held between 6:00 PM and 8:00 PM EST.
Deeper Dive
The ENDURE study provides a standardized framework for evaluating neuromuscular therapies in real-world clinical settings. The upcoming presentations extend the current understanding of the ENDURE study by adding new safety data to the previously established findings.
These findings provide healthcare providers with essential safety information regarding the use of prophylactic immunosuppression alongside Duchenne muscular dystrophy therapies. Patients and families may see these clinical insights influence treatment protocols and management strategies.
The takeaway
Ongoing clinical studies like ENDURE are critical for refining the administration and safety profiles of gene therapies in real-world populations. Professionals should monitor the company website for the release of these abstracts following the meeting embargo.
Further reading
Learn more about advancements in the industry by visiting the Biotech section.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you trust that pharmaceutical companies are transparent about the safety risks of new gene therapies?
